Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Upstream Bio, Inc. (UPB:NASDAQ), powered by AI.
Upstream Bio, Inc. is currently trading at $5.92. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Upstream Bio, Inc. on Alpha Lenz.
Upstream Bio, Inc.'s P/E ratio is -2.2.
“Upstream Bio, Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -35.4%. 3Y revenue CAGR of 33.0% highlights clear growth momentum.”
Ask for details →Upstream Bio Inc. operates within the biotechnology sector, focusing on the development of innovative therapeutic solutions for advanced immunological diseases. The company aims to address unmet medical needs by leveraging cutting-edge scientific research and technology advancements. Upstream Bio Inc. emphasizes the discovery and development of novel biological therapies with the potential to significantly improve patient outcomes in conditions that currently have limited or ineffective treatments. As a player in the biopharmaceutical industry, Upstream Bio collaborates with scientific institutions and industry experts to accelerate the translation of early-stage research into clinically viable products. This focus on therapeutic innovation positions Upstream Bio Inc. as a noteworthy entity in the biotechnology space, contributing to the development of treatments that could have profound impacts on patient care and the broader healthcare landscape. With its commitment to advancing medicine and improving quality of life for individuals with complex immunological disorders, Upstream Bio Inc. holds a critical role in the ongoing evolution of the biopharmaceutical market.
“Upstream Bio, Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -35.4%. 3Y revenue CAGR of 33.0% highlights clear growth momentum.”
Ask for details →Upstream Bio, Inc. (ticker: UPB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 52 employees. Market cap is $319M.
The current price is $5.92 with a P/E ratio of -2.22x and P/B of 0.94x.
ROE is -35.43% and operating margin is -5618.82%. Annual revenue is $3M.